WASHINGTON, D.C. — Federal regulators are proposing new limits on the compounding of several widely used diabetes and weight-loss drugs, a move that could reduce access to lower-cost alternatives when approved versions are available.
What This Means for You
- Compounded versions of certain weight-loss drugs may become restricted
- Pharmacies must rely on FDA-approved products when available
- Public comments will shape the final decision
The U.S. Food and Drug Administration announced it plans to exclude semaglutide, tirzepatide, and liraglutide from a key regulatory list that allows certain facilities to produce compounded drugs from raw ingredients.
Compounding refers to the process of creating customized medications, often by pharmacies or specialized facilities, to meet specific patient needs. These drugs are not FDA-approved in the same way as commercially manufactured medications.
Why the FDA Is Acting
The agency determined there is no demonstrated clinical need — meaning a medically necessary reason — for outsourcing facilities to compound these drugs from bulk substances when FDA-approved versions are already available.
Under federal law, facilities generally cannot compound drugs from bulk ingredients unless the substance is listed on the FDA’s 503B bulks list or the drug is in shortage.
“When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need,” said FDA Commissioner Marty Makary.
What the Decision Covers
The proposal applies to semaglutide, tirzepatide, and liraglutide, medications commonly prescribed to treat diabetes and, in some cases, obesity.
By excluding these substances from the 503B bulks list, the FDA would limit the ability of outsourcing facilities — large-scale compounders that supply hospitals and clinics — to produce alternative versions from raw ingredients.
The agency said it reviewed submitted nominations and did not find sufficient evidence to justify compounding based on patient safety or medical necessity.
Next Steps
The FDA is seeking public input before making a final decision.
Comments can be submitted through June 29, 2026, at https://www.federalregister.gov/public-inspection/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-the-federal-food-drug-and.
The agency will review feedback before determining whether to finalize the proposed restrictions.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.